-
Mashup Score: 1Brahmer's Take: Advancements in 3 Cornerstone Settings of NSCLC - 2 hour(s) ago
Julie R. Brahmer, MD, MSc, FASCO, details practice-changing indications and notable data in the early-stage, neo(adjuvant), and metastatic NSCLC settings.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1OncLive’s October Roundup of Key FDA Approvals in Oncology - 3 hour(s) ago
Here is your snapshot of all therapeutic options that the FDA approved in October 2024 spanning tumor types.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Effectively Targeting c-Met in Colorectal Cancer Is Becoming a Reality With Novel Approaches - 4 hour(s) ago
John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 0
The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1JAK Inhibitors Remain the Gold Standard in Myelofibrosis - 11 hour(s) ago
Daniel DeAngelo MD, PhD, discusses the incorporation of JAK inhibitors into the myelofibrosis treatment paradigm.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC - 12 hour(s) ago
DE397 is the first MAT2A inhibitor to show clinical activity and safety in patients with MTAP-deletion urothelial cancer and non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Ph+ Chronic-Phase Chronic Myeloid Leukemia - 13 hour(s) ago
The FDA has granted accelerated approval to asciminib for newly diagnosed, Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5Expert Sound Bites - 16 hour(s) ago
© 2024 MJH Life Sciences ®. Content developed independently by Onclive
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2Cancer Centers Launch Cancer AI Alliance to Unlock Discoveries, Transform Care Using Cancer Data and Applied AI - 21 hour(s) ago
AWS, Deloitte, Microsoft and NVIDIA bring the latest in AI technology, coordination, and compute to the alliance and back with initial funding.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
Brahmer's Take: Advancements in 3 Cornerstone Settings of NSCLC @JulieBrahmer @HopkinsMedicine @hopkinskimmel #lcsm #oncology #MedTwitter #MedEd https://t.co/iMvXovHIyJ